Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

Stock futures and Treasury yields declined during premarket hours of Tuesday as investors eagerly awaited significant earnings results from Walmart, one of the world's largest retail chains.

The analysts said the paused trial in CSU, a medical term for hives, is the most important of the three studies ... now ...

The company states: “Incyte (INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria ... Phase 2 study evaluating MRGPRX4 in cholestatic ...

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...